NAGE

$4.77

Post-MarketAs of Mar 17, 8:00 PM UTC

Niagen Bioscience, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.77
Potential Downside
0.8%
Whystock Fair Value$4.73
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that con...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$381.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.85
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
28.35%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.73

Recent News

Moby
Mar 5, 2026

Niagen Bioscience Inc Q4 2025 Earnings Call Summary

Moby summary of Niagen Bioscience Inc's Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Mar 5, 2026

A Look At Niagen Bioscience (NAGE) Valuation After New 2026 Double Digit Sales Guidance

Why Niagen Bioscience is back on investor radar Niagen Bioscience (NAGE) has drawn fresh investor attention after issuing 2026 sales guidance that points to 10% to 15% year over year net sales growth, mainly tied to e-commerce expansion and new partnerships. This guidance excludes 2025 revenue from the Analytical Reference Standards and Services segment, so the focus is firmly on the core consumer, ingredients, and e-commerce driven parts of the business. See our latest analysis for Niagen...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 5, 2026

Niagen Bioscience Inc (NAGE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Niagen Bioscience Inc (NAGE) reports robust financial health with significant revenue growth, despite facing increased competition and regulatory hurdles.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 4, 2026

Niagen Bioscience (NAGE) Earnings Transcript

Operator: Ladies and gentlemen, thank you for standing by and welcome to Niagen Bioscience Inc. Fourth Quarter 2025 Earnings Conference Call. This afternoon, Niagen Bioscience Inc. issued a news release announcing the company's financial results for 2025. If you have not reviewed this information, it is available within the Investor Relations section of the Niagen Bioscience Inc. website at www.niagenbioscience.com.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 4, 2026

Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.